The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis

BMC Musculoskeletal Disorders

Volumn 8, Issue , 2007, Pages

  Deane, Andrew ^a   Constancio, Leonor ^a   Fogelman, Ignac ^a   Hampson, Geeta ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCICHEW D3; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; ETIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FEMUR NECK; HIP; HORMONE BLOOD LEVEL; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

AGED; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; SUBSTANCE WITHDRAWAL SYNDROME; TIME; TREATMENT OUTCOME; VITAMIN D; WITHHOLDING TREATMENT;

EID: 33846522959     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-8-3     Document Type: Article

References (21)

1. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. DM Black DE Thompson DC Bauer K Ensrud T Musliner MC Hochberg MC Nevitt S Suryawanshi SR Cummings Fracture Intervention Trial, J Clin Endocrinol Metab 2000 85 11 4118 24 10.1210/jc.85.11.4118 11095442
2. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier JY Reginster Hip Intervention Program Study Group, N Engl J Med 2001 344 5 333 40 10.1056/NEJM200102013440503 11172164
3. Fracture prevention with vitamin D supplementation: a meta-analysis of randomised controlled trials. HA Bischoff-Ferrari WC Willett JB Wong E Giovanni T Dietrich B Dawson-Hughes, JAMA 2005 293 2257 64 10.1001/jama.293.18.2257 15886381
4. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. The RECORD trial Group, Lancet 2005 365 1621 1628 10.1016/S0140-6736(05)63013-9 15885294
5. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. J Porthouse S Cockayne C King L Saxon E Steele T Aspray M Baverstock Y Birks J Dumville R Francis C Iglesias S Puffer A Sutcliffe I Watt DJ Torgensen, British Medical Journal 2005 330 7498 1003 15860827 10.1136/bmj.330.7498.1003
6. Vitamin D concentrations among people aged 65 years and over living in private households and institutions in England: population survey. V Hirani P Primatesta, Age and Ageing 2005 34 485 491 10.1093/ageing/afi153
7. Vitamin D deficiency, muscle function and falls in elderly people. HC Janssen MM Samson HJ Verhaar, Am J Clin Nutr 2002 75 611 615 11916748
8. The high prevalence of inadequate serum vitamin D levels and implications for bone health. JY Reginster, Current Med Res Opinion 2005 21 4 579 585 10.1185/030079905X41435
9. The role of vitamin D in the prevention of osteoporosis. R Vieth, Ann Med 2005 37 4 278 285 10.1080/07853890510007313 16019727
10. Decimal point-Osteoporosis therapy at the 10-year mark. GJ Strewler, N Engl J Med 2004 350 12 1172 1174 10.1056/NEJMp048017 15028820
11. Ten years' experience with alendronate for osteoporosis in post-menopausal women. HG Bone D Hosking JP Devogelaer JR Tucci RD Emkey RP Tonino JA Rodriguez-Portales RW Downs J Gupta AC Santora UA Liberman Alendronate Phase III Osteoporosis Treatment Study Group, N Engl J Med 2004 350 12 1189 1199 10.1056/NEJMoa030897 15028823
12. Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures. SJ Gallagher C Mc Quillian M Harkness F Finlay AD Gallagher T Dixon, Curr Med Res Opinion 2005 21 9 1355 1361 10.1185/030079905X59148
13. Estimates of optimal vitamin D status. B Dawson-Hughes RP Heaney HF Holick P Lips PJ Meunier R Vieth, Osteoporos Int 2005 16 7 713 716 10.1007/s00198-005-1867-7 15776217
14. 3 is probably much higher than what is officially recommended for adults. R Vieth, J Steroid Biochem Mol Biol 2004 89 575 579 10.1016/j.jsbmb.2004.03.038 15225842
15. Vitamin D insufficiency does not affect bone mineral density response to Raloxifene. DM Antoniucci E Vittinghoff T Blackwell DM Black DE Sellmeyer, J Clin Endocrinol Metab 2005 90 4566 4572 10.1210/jc.2005-0290 15899959
16. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. GY Boivin PM Chavassieux AC Santora J Yates PJ Meunier, Bone 2000 27 687 694 10.1016/S8756-3282(00)00376-8 11062357
17. Changes in bone remodeling rate influence the degree of minaralisation of bone. G Boivin PJ Meunier, Connect Tissue Res 2002 43 535 537 12489211
18. Severely suppressed bone turnover: a potential complication of alendronate therapy. CV Odvina JE Zerwech SD Rao N Maalouf FA Gottschalk CYC Pak, J Clin Endo Metab 2005 90 1294 1301 10.1210/jc.2004-0952
19. Treatment of osteoporosis: why, whom, when and how to treat. E Seeman JA Eisman, MJA 2004 180 298 303 15012571
20. Randomised trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the fracture intervention trial long-term extension. KE Ensrud EL Barrett-Connor ZA Schwart AC Santora DC Bauer S Suryawanshi A Feldstein WL Haskell MC Hochberg JC Torner A Lombardi DM Black Fracture Intervention Trial Long-Term Extension Research Group, J Bone Miner Res 2004 19 8 1259 1269 10.1359/JBMR.040326 15231012
21. Cyclical etidronate in the treatment of post-menopausal osteoporosis: efficacy and safety after seven years of treatment. PD Miller NB Watts AA Licata ST Harris HK Genant RD Wasnich PD Ross RD Jackson MS Hoseyni SL Schoenfeld DJ Valent CH Chesnut, 3rd Am J Med 1997 103 6 468 476 10.1016/S0002-9343(97)00278-7 9428829